AgomAb Therapeutics NV (AGMB) stock

AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30

$6.36+0.00 (0.00%)

Close on Nov 13, 2026Market cap $159.00KP/E –Yield –

AgomAb Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

AgomAb Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?